{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:54:43Z","timestamp":1790765683928,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002767","name":"Department of Science and Technology of Hunan Province","doi-asserted-by":"publisher","award":["2022SK2074"],"award-info":[{"award-number":["2022SK2074"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473449"],"award-info":[{"award-number":["82473449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004609","name":"Foundation of Henan Educational Committee","doi-asserted-by":"publisher","award":["19A060"],"award-info":[{"award-number":["19A060"]}],"id":[{"id":"10.13039\/501100004609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computational Biology and Chemistry"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.compbiolchem.2026.109391","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:10:44Z","timestamp":1788538244000},"page":"109391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Construction of efficacy prediction model for T-DXd treatment of HER2-positive and HER2-low expression breast cancer based on hematological indicators: A real-world study"],"prefix":"10.1016","volume":"126","author":[{"given":"Yanfang","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Die","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huachao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longmei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binsheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.compbiolchem.2026.109391_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.freeradbiomed.2014.08.026","article-title":"Manganese superoxide dismutase in breast cancer: from molecular mechanisms of gene regulation to biological and clinical significance","volume":"77","author":"Becuwe","year":"2014","journal-title":"Free. Radic. Biol. Med."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib3","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-10-2962","article-title":"Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER","volume":"17","author":"Brufsky","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-22559-1","article-title":"Prognostic and predictive significance of neutrophil\/lymphocyte ratio for trastuzumab treatment efficacy in HER2-positive breast cancer","volume":"15","author":"Cao","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/cac2.12025","article-title":"Cancer burden of major cancers in China: a need for sustainable actions","volume":"40","author":"Cao","year":"2020","journal-title":"Cancer Commun."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ctrv.2012.01.004","article-title":"A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension","volume":"38","author":"Cavuoto","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib9","article-title":"Association of CDK12 mutations and trastuzumab deruxtecan (TDxd) administration with overall survival (mOS) in HER2+ metastatic breast cancer (mBC)","author":"Enric Alvarez ea","year":"2025","journal-title":"ESMO BC"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.978985","article-title":"Molecular subtypes predict the preferential site of distant metastasis in advanced breast cancer: a nationwide retrospective study","volume":"13","author":"Fan","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib11","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S1470-2045(13)70567-9","article-title":"Breast cancer in China","volume":"15","author":"Fan","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG Oncology Phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib13","article-title":"Prognostic role of inflammatory indices and real-world outcomes in HER2-positive metastatic breast cancer treated with trastuzumab emtansine","volume":"16","author":"Guclu Kantar","year":"2026","journal-title":"Diagnostic"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2013.103","article-title":"HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity","volume":"27","author":"Hanna","year":"2014","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib15","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165916","article-title":"A machine learning framework to trace tumor tissue-of-origin of 13 types of cancer based on DNA somatic mutation","volume":"1866","author":"He","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib17","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fbioe.2020.00394","article-title":"TOOme: a novel computational framework to infer cancer tissue-of-origin by integrating both gene mutation and expression","volume":"8","author":"He","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib18","doi-asserted-by":"crossref","first-page":"17933","DOI":"10.1007\/s00432-023-05496-2","article-title":"Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting","volume":"149","author":"Hu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib20","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.2011.36.2574","article-title":"Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry","volume":"30","author":"Iwamoto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib21","article-title":"Exploratory biomarker analysis of Trastuzumab deruxtecan (TDXd) vs Trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2\u2013positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03)","author":"Jacot","year":"2024","journal-title":"SABCS"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/03936155231154662","article-title":"Prognostic value of alkaline phosphatase and bone-specific alkaline phosphatase in breast cancer: a systematic review and meta-analysis","volume":"38","author":"Jiang","year":"2023","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib23","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib24","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1016\/j.csbj.2021.10.006","article-title":"Applied machine learning in cancer research: a systematic review for patient diagnosis, classification and prognosis","volume":"19","author":"Kourou","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib25","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/ijc.29084","article-title":"Gamma glutamyltransferase, alanine aminotransferase and risk of cancer: systematic review and meta-analysis","volume":"136","author":"Kunutsor","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/bfgp\/elad032","article-title":"Predicting gastric cancer tumor mutational burden from histopathological images using multimodal deep learning","volume":"23","author":"Li","year":"2024","journal-title":"Brief. Funct. Genom."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib27","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.omtn.2020.07.003","article-title":"An improved anticancer drug-response prediction based on an ensemble method integrating matrix completion and ridge regression","volume":"21","author":"Liu","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib28","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib29","article-title":"Predictors of outcome with trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (HER2+ aBC): a multicentric, cohort study (DeReal-REST)","volume":"390P","author":"Luisa Carbognin ea","year":"2025"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib30","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2967\/jnumed.118.222893","article-title":"Introduction to Radiomics","volume":"61","author":"Mayerhoefer","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib31","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbab581","article-title":"A weighted bilinear neural collaborative filtering approach for drug repositioning","volume":"23","author":"Meng","year":"2022","journal-title":"Brief. Bioinform"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib32","article-title":"Drug repositioning based on weighted local information augmented graph neural network","volume":"25","author":"Meng","year":"2024","journal-title":"Brief. Bioinform"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib34","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib35","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1056\/NEJMc1203095","article-title":"Paraneoplastic thrombocytosis in ovarian cancer","volume":"366","author":"Naina","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody\u2013drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a),for HER2 cancer therapy","author":"Nakada","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib37","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-targeting adc with a novel DNA topoisomerase i inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib38","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib39","article-title":"Outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC) according to BRCA and PD-L1 status","author":"Paolo Tarantino ea","year":"2025","journal-title":"ESMO BC"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5010423","article-title":"Oxidative stress and cancer: advances and challenges","volume":"2016","author":"Prasad","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/nu15030769","article-title":"Effects of Vitamin D on cardiovascular risk and oxidative stress","volume":"15","author":"Renke","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.patcog.2021.108197","article-title":"A Unified Hierarchical XGBoost model for classifying priorities for COVID-19 vaccination campaign","volume":"121","author":"Romeo","year":"2022","journal-title":"Pattern Recognit."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41523-023-00538-x","article-title":"Author correction: clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"9","author":"Schettini","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12874-019-0681-4","article-title":"Machine learning in medicine: a practical introduction","volume":"19","author":"Sidey-Gibbons","year":"2019","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib45","article-title":"Indicator regularized non-negative matrix factorization method-based drug repurposing for COVID-19","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12859-024-06032-w","article-title":"CDPMF-DDA: contrastive deep probabilistic matrix factorization for drug-disease association prediction","volume":"26","author":"Tang","year":"2025","journal-title":"BMC Bioinforma."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib47","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.109391","article-title":"Artificial intelligence for breast cancer detection and its health technology assessment: a scoping review","volume":"184","author":"Uwimana","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.834651","article-title":"HER2 Low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer","volume":"9","author":"Venetis","year":"2022","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib50","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib51","article-title":"Association of immuno-inflammatory biomarkers with response to neoadjuvant chemotherapy and prognosis in HER2-positive breast cancer: dual-center clinical evidence","volume":"17","author":"Wu","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib52","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin. Med. J."},{"issue":"16","key":"10.1016\/j.compbiolchem.2026.109391_bib53","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1002\/cncr.32832","article-title":"Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018)","volume":"126","author":"Xu","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf209","article-title":"MMsurv: a multimodal multi-instance multi-cancer survival prediction model integrating pathological images, clinical information, and sequencing data","volume":"26","author":"Yang","year":"2025","journal-title":"Brief. Bioinform"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib55","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.csbj.2021.12.028","article-title":"Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning","volume":"20","author":"Yang","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.compbiolchem.2026.109391_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac448","article-title":"ICSDA: a multi-modal deep learning model to predict breast cancer recurrence and metastasis risk by integrating pathological, clinical and gene expression data","volume":"23","author":"Yao","year":"2022","journal-title":"Brief. Bioinform"},{"key":"10.1016\/j.compbiolchem.2026.109391_bib57","article-title":"The prognostic value of peripheral blood inflammatory markers in patients with HER2-positive metastatic breast cancer treated with pyrotinib","volume":"16","author":"Zhou","year":"2026","journal-title":"Front. Oncol."}],"container-title":["Computational Biology and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927126005189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927126005189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:54:21Z","timestamp":1790762061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476927126005189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":57,"alternative-id":["S1476927126005189"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2026.109391","relation":{},"ISSN":["1476-9271"],"issn-type":[{"value":"1476-9271","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Construction of efficacy prediction model for T-DXd treatment of HER2-positive and HER2-low expression breast cancer based on hematological indicators: A real-world study","name":"articletitle","label":"Article Title"},{"value":"Computational Biology and Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2026.109391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109391"}}